Mesalamine ER
Class
Intestinal anti-inflammatory agents
Subclass
Aminosalicylates
Substance name
Mesalamine, mesalazine, 5-aminosalicylic acid, 5-ASA ER
Brand names
Apriso®, Pentasa®
Common formulations
Capsule
See also
Mesalamine DR (Lialda®, Delzicol®)
Mesalamine (Rowasa®, Canasa®)
Dosage and administration
Adults patients
Ulcerative colitis • Maintenance of remission
Ulcerative colitis • Mild-to-moderate, induction of remission
Indications for use
Labeled indications
Adults
Safety risks
Contraindications
Hypersensitivity to mesalamine or its components or salicylates or aminosalicylates
Warnings and precautions
ALF
Exacerbation of phenylketonuria
Hypersensitivity reactions
Mesalamine-induced acute intolerance syndrome
Minimal change disease, interstitial nephritis, renal failure
Nephrolithiasis
Photosensitivity of skin
Positive urine normetanephrine test
Severe cutaneous adverse reactions
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Continuous renal replacement
Intermittent hemodialysis
Peritoneal dialysis
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Use only if benefits outweigh potential risks.
Unknown drug levels in breastfed infants.
May potentially cause adverse effects in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource